23andMe Overview

  • Founded
  • 2006

Founded
  • Status
  • Public

  • Employees
  • 796

Employees
  • Stock Symbol
  • ME

Stock Symbol
  • Investments
  • 4

  • Share Price
  • $2.69

  • (As of Friday Closing)

23andMe General Information

Description

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

Contact Information

Website
www.23andme.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Information Services (B2C)
Other Devices and Supplies
Biotechnology
Stock Exchange
NAS
Primary Office
  • 223 North Mathilda Avenue
  • Sunnyvale, CA 94086
  • United States
+1 (800) 000-0000

23andMe Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

23andMe Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.69 $2.75 $2.02 - $6.31 $1.23B 455M 2.64M -$0.72

23andMe Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 896,092 1,214,005
Revenue 297,622 271,893 243,920 305,463
EBITDA (285,854) (195,099) (163,628) (233,818)
Net Income (314,537) (217,490) (183,619) (250,863)
Total Assets 1,040,732 1,152,068 452,098
Total Debt 81,881 86,308 93,722 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

23andMe Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer persona
Laboratory Services (Healthcare)
Sunnyvale, CA
796 As of 2022
00.000
000000000 00.000

000000

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000 00000000
Foster City, CA
000 As of 0000
00000
0000000 0000 00000

00000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000000
Aliso Viejo, CA
000 As of 0000
00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

23andMe Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MedGenome Private Equity-Backed Foster City, CA 000 00000 0000000 0000 00000
00000 00000000 Corporate Backed or Acquired Aliso Viejo, CA 000 000000&0
000000 000000 Venture Capital-Backed South Plainfield, NJ 00 000000000 -
00000 000000000 Venture Capital-Backed San Diego, CA 00 00000 0000000 0000
000000000 00000000 Formerly VC-backed Espoo, Finland 000 000.00 000000&0 000.00
You’re viewing 5 of 15 competitors. Get the full list »

23andMe Patents

23andMe Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220115139-A1 Formatting and storage of genetic markers Pending 09-Oct-2020 000000000 0
US-20220051751-A1 Ancestry composition determination Pending 13-Aug-2020 000000000
CA-3178417-A1 Anti-cd200r1 antibodies and methods of use thereof Pending 29-May-2020
AU-2021281417-A1 Anti-cd200r1 antibodies and methods of use thereof Pending 29-May-2020 00000000000
US-20210371521-A1 Anti-cd200r1 antibodies and methods of use thereof Pending 29-May-2020 C07K16/2803 0
To view 23andMe’s complete patent history, request access »

23andMe Executive Team (44)

Name Title Board Seat Contact Info
Anne Wojcicki Chief Executive Officer & Chairman
Paul Johnson Chief Operating Officer, Operations
Kathy Hibbs JD Chief Administrative Officer, Administration
Joseph Arron MD Chief Scientific Officer
Mike Polcari Vice President, Chief Architect, Software Architect and Director of Software Engineering
You’re viewing 5 of 44 executive team members. Get the full list »

23andMe Board Members (12)

Name Representing Role Since
Anne Wojcicki 23andMe Chief Executive Officer & Chairman 000 0000
Evan Lovell VG Acquisition Board Member 000 0000
Neal Mohan Self Board Member 000 0000
Patrick Chung JD Xfund Board Member 000 0000
Peter Taylor Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

23andMe Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

23andMe Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 23andMe‘s full profile, request access.

Request a free trial

23andMe Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 01-Nov-2021 0000000000 00000 Other Healthcare Services 0000 0000
000000 (00000 07-Apr-2021 0000 00000 00.00 Laboratory Services (Healthcare)
000000 00 000 20-Jul-2015 00000 0000 0000 Other Healthcare Services 0000 0000
CureTogether 10-Jul-2012 Merger/Acquisition Decision/Risk Analysis 0000 0000
To view 23andMe’s complete investments and acquisitions history, request access »

23andMe Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000 Other Healthcare Services San Francisco, CA 0000
To view 23andMe’s complete subsidiaries history, request access »

23andMe ESG

Risk Overview

Risk Rating

Updated October, 13, 2022

25.61 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view 23andMe’s complete esg history, request access »

23andMe Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00 000000 20-Jul-2015 00000 00000 00 0000 Completed
  • 14 buyers
To view 23andMe’s complete exits history, request access »